Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureResearch graph
References from Bortezomib Restores Venetoclax Sensitivity in Acute Myeloid Leukemia Cell Lines with Intrinsic and Acquired Resistance. Local targets link to admitted publications; unresolved targets remain external evidence.
Acute myeloid leukaemia
10.1038/nrdp.2016.10 · 2016 · External reference
Epidemiology of acute myeloid leukemia: recent progress and enduring challenges
10.1016/j.blre.2019.04.005 · 2019 · External reference
Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia
10.1182/blood-2018-08-868752 · 2019 · External reference
Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial
10.1182/blood.2020004856 · 2020 · External reference
The path to venetoclax resistance is paved with mutations, metabolism, and more
10.1126/scitranslmed.abo6891 · 2022 · External reference
Venetoclax therapy and emerging resistance mechanisms in acute myeloid leukaemia
10.1038/s41419-024-06810-7 · 2024 · External reference
Acquired resistance to venetoclax plus azacitidine in acute myeloid leukemia: in vitro models and mechanisms
10.1016/j.bcp.2023.115759 · 2023 · External reference
A novel MCL1 inhibitor combined with venetoclax rescues venetoclax-resistant acute myelogenous leukemia
10.1158/2159-8290.cd-18-0140 · 2018 · External reference
Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia
10.1038/s41392-021-00870-3 · 2022 · External reference
RAS-mutant leukaemia stem cells drive clinical resistance to venetoclax
10.1038/s41586-024-08137-x · 2024 · External reference
Acquired mutations in BAX confer resistance to BH3-mimetic therapy in acute myeloid leukemia
10.1182/blood.2022016090 · 2023 · External reference
BCL-2 family proteins: changing partners in the dance towards death
10.1038/cdd.2017.186 · 2018 · External reference
MCL-1 inhibitors, fast-lane development of a new class of anti-cancer agents
10.1186/s13045-020-01007-9 · 2020 · External reference
Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial
10.1016/s1470-2045(20)30525-8 · 2020 · External reference
Establishment and characterization of a unique human cell line that proliferates dependently on GM-CSF, IL-3, or erythropoietin
10.1002/jcp.1041400219 · 1989 · External reference
The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models
10.1038/nature19830 · 2016 · External reference
5-Azacitidine induces NOXA to prime AML cells for venetoclax-mediated apoptosis
10.1158/1078-0432.ccr-19-1900 · 2020 · External reference
Pevonedistat and azacitidine upregulate NOXA (PMAIP1) to increase sensitivity to venetoclax in preclinical models of acute myeloid leukemia
10.3324/haematol.2020.272609 · 2022 · External reference
The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status
10.1182/blood-2005-05-2091 · 2006 · External reference
Role of NOXA and its ubiquitination in proteasome inhibitor-induced apoptosis in chronic lymphocytic leukemia cells
10.3324/haematol.2010.022368 · 2010 · External reference
KLF9 is a novel transcriptional regulator of bortezomib- and LBH589-induced apoptosis in multiple myeloma cells
10.1182/blood-2011-04-346676 · 2012 · External reference
The BCL-2 inhibitor ABT-199/venetoclax synergizes with proteasome inhibition via transactivation of the MCL-1 antagonist NOXA
10.1038/s41420-022-01009-1 · 2022 · External reference
Mechanisms of fenretinide-induced apoptosis
10.1007/s10495-006-9289-3 · 2006 · External reference
Fenretinide via NOXA induction, enhanced activity of the BCL-2 inhibitor venetoclax in high BCL-2–expressing neuroblastoma preclinical models
10.1158/1535-7163.mct-19-0385 · 2019 · External reference
Voruciclib, a clinical stage oral CDK9 inhibitor, represses MCL-1 and sensitizes high-risk diffuse large B-cell lymphoma to BCL2 inhibition
10.1038/s41598-017-18368-w · 2017 · External reference
Inhibition of CDK9 by voruciclib synergistically enhances cell death induced by the Bcl-2 selective inhibitor venetoclax in preclinical models of acute myeloid leukemia
10.1038/s41392-020-0112-3 · 2020 · External reference
Vorinostat-induced apoptosis in mantle cell lymphoma is mediated by acetylation of proapoptotic BH3-only gene promoters
10.1158/1078-0432.ccr-10-3412 · 2011 · External reference
Pharmacological brake-release of mRNA translation enhances cognitive memory
10.7554/elife.00498 · 2013 · External reference
ISRIB blunts the integrated stress response by allosterically antagonising the inhibitory effect of phosphorylated eIF2 on eIF2B
10.1016/j.molcel.2020.10.031 · 2021 · External reference
Pharmacological properties, central nervous system effects, and potential therapeutic applications of atipamezole, a selective alpha2-adrenoceptor antagonist
10.1111/j.1527-3458.2005.tb00047.x · 2005 · External reference
Searching for drug synergy in complex dose–response landscapes using an interaction potency model
10.1016/j.csbj.2015.09.001 · 2015 · External reference
SynergyFinder plus: toward better interpretation and annotation of drug combination screening datasets
10.1016/j.gpb.2022.01.004 · 2022 · External reference
Functional genomic landscape of acute myeloid leukaemia
10.1038/s41586-018-0623-z · 2018 · External reference
Integrative analysis of drug response and clinical outcome in acute myeloid leukemia
10.1016/j.ccell.2022.07.002 · 2022 · External reference
Defining a cancer dependency map
10.1016/j.cell.2017.06.010 · 2017 · External reference
Drug combination sensitivity scoring facilitates the discovery of synergistic and efficacious drug combinations in cancer
10.1371/journal.pcbi.1006752 · 2019 · External reference
Clonal hematopoiesis, myeloid disorders and BAX -mutated myelopoiesis in patients receiving venetoclax for CLL
10.1182/blood.2021012775 · 2022 · External reference
Cytarabine-resistant FLT3-ITD leukemia cells are associated with TP53 mutation and multiple pathway alterations–possible therapeutic efficacy of cabozantinib
10.3390/ijms20051230 · 2019 · External reference
Clinical implications of subclonal TP53 mutations in acute myeloid leukemia
10.3324/haematol.2018.205013 · 2019 · External reference
TP53 mutations in de novo acute myeloid leukemia patients: longitudinal follow-ups show the mutation is stable during disease evolution
10.1038/bcj.2015.59 · 2015 · External reference
Defining function of wild-type and three patient-specific TP53 mutations in a zebrafish model of embryonal rhabdomyosarcoma
10.7554/elife.68221 · 2023 · External reference
TP53 disruptive mutations lead to head and neck cancer treatment failure through inhibition of radiation-induced senescence
10.1158/1078-0432.ccr-11-2260 · 2012 · External reference
Effect of the p53 P72R polymorphism on mutant TP53 allele selection in human cancer
10.1093/jnci/djab019 · 2021 · External reference
Exploiting the pro-apoptotic function of NOXA as a therapeutic modality in cancer
10.1080/14728222.2017.1349754 · 2017 · External reference
Bax and Bak pores: are we closing the circle?
10.1016/j.tcb.2016.11.004 · 2017 · External reference
Combined inhibition of BCL-2 and MCL-1 overcomes BAX deficiency-mediated resistance of TP53-mutant acute myeloid leukemia to individual BH3 mimetics
10.1038/s41408-023-00830-w · 2023 · External reference
Venetoclax and bortezomib in relapsed/refractory early T-cell precursor acute lymphoblastic leukemia
10.1200/po.19.00172 · 2019 · External reference
